SG11201901961SA - Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x - Google Patents
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor xInfo
- Publication number
- SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA SG 11201901961S A SG11201901961S A SG 11201901961SA
- Authority
- SG
- Singapore
- Prior art keywords
- coagulation factor
- bleeding
- international
- activated
- recognizes
- Prior art date
Links
- 108010076282 Factor IX Proteins 0.000 title abstract 5
- 108010014173 Factor X Proteins 0.000 title abstract 4
- 229940105774 coagulation factor ix Drugs 0.000 title abstract 4
- 102100029117 Coagulation factor X Human genes 0.000 title abstract 3
- 229940105756 coagulation factor x Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000013831 Coagulation factor IX Human genes 0.000 title 2
- 230000000740 bleeding effect Effects 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383933P | 2016-09-06 | 2016-09-06 | |
| US201662437281P | 2016-12-21 | 2016-12-21 | |
| US201762485514P | 2017-04-14 | 2017-04-14 | |
| PCT/JP2017/031933 WO2018047813A1 (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901961SA true SG11201901961SA (en) | 2019-04-29 |
Family
ID=61561893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901961SA SG11201901961SA (en) | 2016-09-06 | 2017-09-05 | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11352438B2 (ja) |
| EP (1) | EP3509637A4 (ja) |
| JP (2) | JP7125932B2 (ja) |
| KR (2) | KR102560808B1 (ja) |
| CN (1) | CN109661241A (ja) |
| AU (1) | AU2017325240A1 (ja) |
| BR (1) | BR112019003989A2 (ja) |
| CA (1) | CA3035327A1 (ja) |
| CR (1) | CR20190162A (ja) |
| IL (1) | IL265144B1 (ja) |
| MA (1) | MA46200A (ja) |
| MX (1) | MX2019002510A (ja) |
| RU (1) | RU2766233C2 (ja) |
| SG (1) | SG11201901961SA (ja) |
| TW (1) | TWI786061B (ja) |
| WO (1) | WO2018047813A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| RU2620071C2 (ru) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| IL265144B1 (en) | 2016-09-06 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Methods for using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| JP2021502984A (ja) | 2017-11-15 | 2021-02-04 | ノヴォ ノルディスク アー／エス | Ｆｘ活性化を促進する第ｘ因子結合剤 |
| FR3082427B1 (fr) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
| RS62848B1 (sr) | 2018-12-21 | 2022-02-28 | Kymab Ltd | Dvojno-specifično fixaxfx antitelo sa zajedničkim lakim lancem |
| TW202207984A (zh) * | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 |
| US20220305122A1 (en) * | 2019-10-11 | 2022-09-29 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition |
| USD967377S1 (en) | 2020-10-08 | 2022-10-18 | Samsung Electronics Co., Ltd. | Air purifier |
| KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
| KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
| KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU649952B2 (en) | 1989-12-11 | 1994-06-09 | Immunomedics Inc. | Method for antibody targeting of diagnostic or therapeutic agents |
| TW212184B (ja) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| JPH05184383A (ja) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | 二重特異性抗体 |
| JPH05199894A (ja) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | 二重特異性抗体および抗体含有薬剤 |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| JPH05304992A (ja) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | ハイブリッド・モノクローナル抗体および抗体含有薬剤 |
| JPH06104071A (ja) | 1991-08-30 | 1994-04-15 | Jasco Corp | 発熱体セラミックス溶接加工方法 |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| JPH05203652A (ja) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | 抗体酵素免疫分析法 |
| JPH05213775A (ja) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Ｂｆａ抗体 |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0660937A1 (en) | 1993-07-01 | 1995-07-05 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| DK0771216T3 (da) | 1994-07-11 | 2001-02-05 | Scripps Research Inst | Fremgangsmåder og præparater til specifik koagulering af tumorvaskulatur |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| AU4289496A (en) | 1994-12-02 | 1996-06-19 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| JP3032287U (ja) | 1996-06-10 | 1996-12-17 | 幸喜 高橋 | 人 形 |
| JPH10165184A (ja) | 1996-12-16 | 1998-06-23 | Tosoh Corp | 抗体、遺伝子及びキメラ抗体の製法 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| BR9909382A (pt) | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| JP2004511430A (ja) | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | 二重特異性免疫グロブリン様抗原結合蛋白および製造方法 |
| JP4908721B2 (ja) | 2000-07-17 | 2012-04-04 | 中外製薬株式会社 | 生理活性を有するリガンドのスクリーニング方法 |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| WO2002032925A2 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2424371A1 (en) | 2000-10-20 | 2003-04-01 | Chugai Seiyaku Kabushiki Kaisha | Agonistic monoclonal antibody fragments |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| AU2003227504A1 (en) | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| US7732149B2 (en) | 2002-04-26 | 2010-06-08 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening agonistic antibodies |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| WO2004060919A1 (ja) | 2002-12-26 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | ヘテロ受容体に対するアゴニスト抗体 |
| US8337841B2 (en) | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
| EP1598074B1 (en) | 2003-02-28 | 2019-01-02 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
| GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
| US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP2311945A1 (en) | 2003-10-14 | 2011-04-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies substituting for functional proteins |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| JP4460414B2 (ja) | 2004-10-06 | 2010-05-12 | 日本電信電話株式会社 | 血圧計 |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| EP1876236B9 (en) | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| KR101856792B1 (ko) | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| BR112012031920A2 (pt) | 2010-06-14 | 2017-05-16 | Paion Deutschland Gmbh | tratamento de coagulopatias com hiperfibrinólise. |
| RU2620071C2 (ru) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| CA2860543C (en) | 2012-03-08 | 2018-04-24 | F. Hoffmann-La Roche Ag | Abeta antibody formulation |
| JP2017500372A (ja) * | 2013-11-04 | 2017-01-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 出血または凝固性低下と関係する容態の治療療法または予防療法 |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| JP6962819B2 (ja) | 2015-04-10 | 2021-11-05 | アディマブ， エルエルシー | 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法 |
| CN107454906B (zh) | 2015-04-17 | 2022-05-27 | 豪夫迈·罗氏有限公司 | 使用凝固因子和多特异性抗体的联合治疗 |
| JP2018123055A (ja) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物 |
| TWI797073B (zh) | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | 包含雙特異性抗體建構物之醫藥組合物 |
| TW202402326A (zh) | 2016-04-28 | 2024-01-16 | 日商中外製藥股份有限公司 | 含抗體製劑 |
| IL265144B1 (en) | 2016-09-06 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Methods for using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
| US20210107994A1 (en) | 2017-03-31 | 2021-04-15 | Public University Corporation Nara Medical University | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
| PE20210553A1 (es) | 2017-11-01 | 2021-03-17 | Chugai Pharmaceutical Co Ltd | Variantes e isoformas de anticuerpos con actividad biologica reducida |
| TW202207984A (zh) | 2019-10-11 | 2022-03-01 | 日商中外製藥股份有限公司 | 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品 |
-
2017
- 2017-09-05 IL IL265144A patent/IL265144B1/en unknown
- 2017-09-05 US US16/330,269 patent/US11352438B2/en active Active
- 2017-09-05 CR CR20190162A patent/CR20190162A/es unknown
- 2017-09-05 MA MA046200A patent/MA46200A/fr unknown
- 2017-09-05 SG SG11201901961SA patent/SG11201901961SA/en unknown
- 2017-09-05 BR BR112019003989A patent/BR112019003989A2/pt unknown
- 2017-09-05 MX MX2019002510A patent/MX2019002510A/es unknown
- 2017-09-05 RU RU2019109464A patent/RU2766233C2/ru active
- 2017-09-05 CA CA3035327A patent/CA3035327A1/en active Pending
- 2017-09-05 EP EP17848753.4A patent/EP3509637A4/en active Pending
- 2017-09-05 KR KR1020197009689A patent/KR102560808B1/ko active IP Right Grant
- 2017-09-05 CN CN201780054106.1A patent/CN109661241A/zh active Pending
- 2017-09-05 WO PCT/JP2017/031933 patent/WO2018047813A1/en unknown
- 2017-09-05 AU AU2017325240A patent/AU2017325240A1/en active Pending
- 2017-09-05 JP JP2019511669A patent/JP7125932B2/ja active Active
- 2017-09-05 TW TW106130277A patent/TWI786061B/zh active
- 2017-09-05 KR KR1020237025275A patent/KR20230117462A/ko not_active Application Discontinuation
-
2022
- 2022-05-31 US US17/828,752 patent/US20220315667A1/en not_active Abandoned
- 2022-08-15 JP JP2022129184A patent/JP2022166174A/ja active Pending
-
2023
- 2023-01-19 US US18/156,559 patent/US20230159658A1/en not_active Abandoned
- 2023-09-14 US US18/466,900 patent/US20240052058A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019530654A (ja) | 2019-10-24 |
| AU2017325240A1 (en) | 2019-05-02 |
| WO2018047813A1 (en) | 2018-03-15 |
| US20190194352A1 (en) | 2019-06-27 |
| EP3509637A4 (en) | 2020-05-27 |
| RU2019109464A (ru) | 2020-10-08 |
| BR112019003989A2 (pt) | 2019-05-28 |
| TWI786061B (zh) | 2022-12-11 |
| KR102560808B1 (ko) | 2023-07-27 |
| MX2019002510A (es) | 2019-06-24 |
| US20240052058A1 (en) | 2024-02-15 |
| RU2766233C2 (ru) | 2022-02-10 |
| MA46200A (fr) | 2019-07-17 |
| US20220315667A1 (en) | 2022-10-06 |
| JP7125932B2 (ja) | 2022-08-25 |
| IL265144B1 (en) | 2024-06-01 |
| KR20190044673A (ko) | 2019-04-30 |
| CN109661241A (zh) | 2019-04-19 |
| KR20230117462A (ko) | 2023-08-08 |
| TW201822815A (zh) | 2018-07-01 |
| CA3035327A1 (en) | 2018-03-15 |
| IL265144A (ja) | 2019-04-30 |
| JP2022166174A (ja) | 2022-11-01 |
| EP3509637A1 (en) | 2019-07-17 |
| US11352438B2 (en) | 2022-06-07 |
| RU2019109464A3 (ja) | 2020-12-21 |
| US20230159658A1 (en) | 2023-05-25 |
| CR20190162A (es) | 2019-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201801401UA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a |